首页> 外文期刊>Clinical drug investigation >Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study
【24h】

Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study

机译:黄嘌呤氧化酶抑制剂非布索坦对高尿酸血症性高血压患者心血管风险的影响:一项前瞻性开放性先导研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Objective There is growing evidence of an association between high uric acid (UA) levels and cardiovascular disease (CVD). We hypothesized that febuxostat, a xanthine oxidase inhibitor, may be associated with suppressing the renin-angiotensin-aldosterone system (RAAS) and improving renal function in hyperurecemic patients with hypertension.
机译:背景与目的越来越多的证据表明高尿酸(UA)水平与心血管疾病(CVD)之间存在关联。我们假设黄嘌呤氧化酶抑制剂非布索坦可能与抑制高尿酸血症性高血压患者的肾素-血管紧张素-醛固酮系统(RAAS)和改善肾功能有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号